Picture of Rein Therapeutics logo

RNTX — Rein Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Aileron Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

* Aileron Therapeutics Inc  ALRN.OQ  reported a quarterly
adjusted loss of 6 cents​​ per share for the quarter ended in
June. The mean expectation of three analysts for the quarter was
for a loss of 7 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Aileron Therapeutics Inc's reported EPS for the quarter was a
loss of 6 cents​.
* The mean earnings estimate of analysts had fallen by about 10%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Aileron Therapeutics Inc shares had fallen by 19.2% this
quarter and lost 2.9% so far this year.
* The company reported a quarterly loss of $5.69 million.
* Wall Street's median 12-month price target for Aileron
Therapeutics Inc is $3.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 11 at 09:34 p.m.  ​All
figures in US dollars unless otherwise stated

Recent news on Rein Therapeutics

See all news